ResMed to acquire German out-of-hospital software leader MEDIFOX DAN for ~$1B

RESMED INC

Purchase price ~US$1.0B (€950M); expected to close by Dec 31, 2022 subject to German regulatory clearances.
MEDIFOX DAN CY2021 pro forma revenue ~$83M, adjusted EBITDA ~$35M; deal expected accretive to non-GAAP EPS.
Expands ResMed's SaaS business into Germany; MEDIFOX DAN brand and management to continue under ResMed SaaS.
Co-managing directors Dr. Thorsten Schliebe and Christian Städtler will remain, reporting to ResMed SaaS President.
ResMed to fund via existing credit facilities; Evercore and DLA Piper serving as advisors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.